Components of metabolic syndrome have been jointly linked with an increased risk of dying from prostate cancer, according to a recent study.
Small urology programs saw increase in at-home, in-section matches during COVID-19 pandemic
In 2021, small urology programs had 28.1% spots filled by applicants at their home program, compared with 16.2% between 2016 and 2020.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Phase 3 ARASTEP study to investigate darolutamide plus ADT for hormone-sensitive prostate cancer
"With ARASTEP, we are optimistic about the potential to help patients at this earlier stage of [prostate cancer]," says Tara Frenkl, MD.
Speaking of Urology: ASCO GU 2023 Highlights
Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
Hormone therapy plus current treatments improves survival in prostate cancer
Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
CBD oil does not reduce pain in patients after ureteroscopy
"While CBD oil appears safe, it does not seem to reduce pain or discomfort during the typically brief recovery period after this common procedure,” says Karen Stern, MD.
2 Clarke Drive Cranbury, NJ 08512